{"commentary":{"count":28,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":12,"x_thread":9,"podcast":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04612751\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TROPION-Lung04","nct_id":"NCT04612751","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-lung04-nct04612751. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TROPION-Lung04","arms":[{"description":"Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy","label":"Cohort 2","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy","label":"Cohort 3","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy","label":"Cohort 4","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC","label":"Cohort 5","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC","label":"Cohort 6","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC","label":"Cohort 7","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC","label":"Cohort 8","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC","label":"Cohort 9","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC","label":"Cohort 10","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + MEDI5752 in participants with treatment-naïve NSCLC","label":"Cohort 11","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC","label":"Cohort 12","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC","label":"Cohort 13","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with treatment-naïve NSCLC","label":"Cohort 14","type":"EXPERIMENTAL"},{"description":"Datopotamab deruxtecan (Dato-DXd) + Durvalumab + carboplatin in participants with treatment-naïve NSCLC","label":"Cohort 4A","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-05-04","type":"ESTIMATED"},"conditions":["Advanced or Metastatic NSCLC"],"enrollment":{"count":155,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Datopotamab deruxtecan","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"AZD2936","type":"DRUG"},{"name":"MEDI5752","type":"DRUG"},{"name":"AZD7789","type":"DRUG"}],"last_update":"2026-07-27","lead_sponsor":"AstraZeneca","official_title":"A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-05-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of participants with DLTs; TEAEs and other safety parameters during the study.","timeFrame":"DLTs: within first cycle (21 days); TEAEs and other safety parameters: when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up (approximately 60 months)"}],"references":[],"start_date":{"date":"2021-02-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04612751"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-lung04-nct04612751"}